Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) Cyclically Adjusted FCF per Share: ¥-0.93 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688076 Sinopep Allsino Bio Pharmaceutical Co Ltd SHSE:688076
67 GF Score
Price ¥27.54
GF Value ¥59.15
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Sinopep Allsino Bio Pharmaceutical Co Cyclically Adjusted FCF per Share?

Sinopep Allsino Bio Pharmaceutical Co SHSE:688076 +1.06% 67 Cyclically Adjusted FCF per Share is ¥-0.93 as of Mar. 2026. GuruFocus rates SHSE:688076 with a GF Score™ of 67/100 and a GF Value™ of ¥59.15 (Significantly Undervalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Sinopep Allsino Bio Pharmaceutical Co's adjusted free cash flow per share for the three months ended in Mar. 2026 was ¥-0.061. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ¥-0.93 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-04), Sinopep Allsino Bio Pharmaceutical Co's current stock price is ¥27.54. Sinopep Allsino Bio Pharmaceutical Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was ¥-0.93. Sinopep Allsino Bio Pharmaceutical Co's Cyclically Adjusted Price-to-FCF of today is .


Sinopep Allsino Bio Pharmaceutical Co  (SHSE:688076) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Sinopep Allsino Bio Pharmaceutical Co Cyclically Adjusted FCF per Share Related Terms


Sinopep Allsino Bio Pharmaceutical Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Sinopep Allsino Bio Pharmaceutical Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopep Allsino Bio Pharmaceutical Co Cyclically Adjusted FCF per Share Chart

Sinopep Allsino Bio Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.95

Sinopep Allsino Bio Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.96 -0.95 -0.93

SHSE:688076 vs VRTX, REGN, RVMD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Sinopep Allsino Bio Pharmaceutical Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinopep Allsino Bio Pharmaceutical Co Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinopep Allsino Bio Pharmaceutical Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sinopep Allsino Bio Pharmaceutical Co's Cyclically Adjusted Price-to-FCF falls into.


SHSE:688076
67GF Score
Sinopep Allsino Bio Pharmaceutical Co Ltd SHSE:688076
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinopep Allsino Bio Pharmaceutical Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sinopep Allsino Bio Pharmaceutical Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.061/116.3033*116.3033
=-0.061

Current CPI (Mar. 2026) = 116.3033.

Sinopep Allsino Bio Pharmaceutical Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201512 0.000 100.600 0.000
201606 0.000 101.400 0.000
201612 0.000 102.600 0.000
201703 -0.120 103.200 -0.135
201706 0.274 103.100 0.309
201709 -0.184 104.100 -0.206
201712 -0.424 104.500 -0.472
201803 -0.052 105.300 -0.057
201806 -0.308 104.900 -0.341
201809 0.018 106.600 0.020
201812 -0.174 106.500 -0.190
201903 -0.446 107.700 -0.482
201906 -0.222 107.700 -0.240
201909 0.313 109.800 0.332
201912 0.052 111.200 0.054
202003 -0.185 112.300 -0.192
202006 -0.119 110.400 -0.125
202009 0.426 111.700 0.444
202012 0.027 111.500 0.028
202103 -0.124 112.662 -0.128
202106 0.163 111.769 0.170
202109 -0.187 112.215 -0.194
202112 -0.065 113.108 -0.067
202203 -0.513 114.335 -0.522
202206 -0.292 114.558 -0.296
202209 -0.339 115.339 -0.342
202212 -0.481 115.116 -0.486
202303 0.157 115.116 0.159
202306 -0.415 114.558 -0.421
202309 -0.401 115.339 -0.404
202312 -0.366 114.781 -0.371
202403 -0.287 115.227 -0.290
202406 -0.131 114.781 -0.133
202409 -0.761 115.785 -0.764
202412 -1.019 114.893 -1.032
202503 -0.667 115.116 -0.674
202506 -0.507 114.907 -0.513
202509 -0.859 115.471 -0.865
202512 -0.147 115.832 -0.148
202603 -0.061 116.303 -0.061

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ¥-0.93 mean?
Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) has a Cyclically Adjusted FCF per Share of ¥-0.93 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Sinopep Allsino Bio Pharmaceutical Co and its competitors.
Is Sinopep Allsino Bio Pharmaceutical Co's Cyclically Adjusted FCF per Share too high?
Sinopep Allsino Bio Pharmaceutical Co's current Cyclically Adjusted FCF per Share is ¥-0.93. Overall, Sinopep Allsino Bio Pharmaceutical Co has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopep Allsino Bio Pharmaceutical Co's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Sinopep Allsino Bio Pharmaceutical Co's Cyclically Adjusted FCF per Share of ¥-0.93 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Sinopep Allsino Bio Pharmaceutical Co and its competitors. Sinopep Allsino Bio Pharmaceutical Co's current Cyclically Adjusted FCF per Share is ¥-0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopep Allsino Bio Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥59.15, compared to a current price of ¥27.54 — trading 53.4% below its estimated fair value. The current Cyclically Adjusted FCF per Share is ¥-0.93. Sinopep Allsino Bio Pharmaceutical Co's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076), the current Cyclically Adjusted FCF per Share is ¥-0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopep Allsino Bio Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥27.54 is trading 53.4% below its estimated GF Value™ of ¥59.15. GuruFocus considers Sinopep Allsino Bio Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for SHSE:688076:

  • Cyclically Adjusted FCF per Share: ¥-0.93
  • GF Value™: ¥59.15 vs. price of ¥27.54 (53.4% below fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688076 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sinopep Allsino Bio Pharmaceutical Co Business Description

Address No. 28, Linpu Road, Economic and Technological Development Zone, Jiangsu Province, Lianyungang, CHN, 222069
Sinopep Allsino Bio Pharmaceutical Co Ltd is a market-oriented, research and development and innovation-driven biomedical enterprise focusing on the research, development, production and sales of peptide drugs and small molecule chemical drugs.
67GF Score

Get the complete analysis for SHSE:688076

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥27.54
Price
¥59.15
GF Value